Personalis, Inc. PSNL
Personalis develops, markets, and sells advanced cancer genomic testing services. Our testing services are used by physicians to detect residual or recurrent cancer in patients, monitor cancer response to therapy, and uncover insights for therapy selection. Our testing services are used by pharmaceutical companies for translational research, biomarker discovery, the development of personalized cancer therapies, and clinical trials. We also provide whole exome sequencing services for other diagnostic companies and whole genome sequencing services for population sequencing initiatives.
We perform our testing services in a large-scale, high-quality, Clinical Laboratory Improvement Amendments of 1988 ("CLIA") certified and College of American Pathologists ("CAP") accredited, laboratory located in our 100,000 square foot headquarters in Fremont, California. We were incorporated under the laws of the state of Delaware in 2011 under the name Personalis, Inc. and became a publicly-traded company in 2019.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $69.6M | $84.6M | $73.5M | $65.0M | $85.5M | $78.6M | $65.2M | $37.8M | $9.4M | — |
| Cost of revenue | $53.9M | $57.8M | $55.3M | $51.7M | $53.8M | $58.5M | $43.1M | $26.0M | $11.7M | — |
| Gross profit | $15.8M | $26.8M | $18.2M | $13.3M | $31.7M | $20.1M | $22.1M | $11.8M | -$2.3M | — |
| R&D | $50.3M | $48.9M | $64.8M | $64.9M | $49.3M | $28.6M | $22.4M | $14.3M | $9.9M | — |
| SG&A | $53.6M | $46.2M | $49.7M | $64.0M | $47.7M | $33.7M | $22.1M | $11.3M | $9.9M | — |
| Total operating expenses | $157.7M | $152.9M | $183.4M | $180.6M | $150.8M | $120.8M | $87.6M | $51.5M | $31.6M | — |
| Operating income | -$88.1M | -$68.3M | -$109.9M | -$115.5M | -$65.4M | -$42.1M | -$22.4M | -$13.8M | -$22.2M | — |
| Interest expense | $205.0K | $24.0K | $110.0K | $201.0K | $184.0K | $2.0K | $1.1M | $1.9M | $1.3M | — |
| Pre-tax income | -$81.2M | -$81.3M | -$108.2M | -$113.3M | -$65.2M | -$41.2M | -$25.1M | -$19.9M | -$23.6M | — |
| Income tax | $21.0K | $18.0K | $83.0K | $40.0K | $14.0K | $57.0K | $9.0K | $7.0K | $5.0K | — |
| Net income | -$81.3M | -$81.3M | -$108.3M | -$113.3M | -$65.2M | -$41.3M | -$25.1M | -$19.9M | -$23.6M | — |
| EPS, basic | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | — | — | — | — |
| EPS, diluted | -0.91 | -1.37 | -2.25 | -2.48 | -1.49 | -1.20 | -1.39 | -6.49 | -7.78 | — |
| Shares, diluted (wtd. avg.) | 89.2M | 59.3M | 48.2M | 45.7M | 43.9M | 34.4M | 18.0M | 3.1M | 3.0M | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $124.2M | $91.4M | $57.0M | $89.1M | $105.6M | $68.5M | $55.0M | $19.7M | — | — |
| Short-term investments | $115.7M | $93.6M | $57.2M | $78.5M | $181.5M | $134.8M | $73.2M | — | — | — |
| Receivables | $16.2M | $8.1M | $17.7M | $16.6M | $18.5M | $6.3M | $3.3M | $4.5M | — | — |
| Total current assets | $268.0M | $203.0M | $146.7M | $199.7M | $318.2M | $220.7M | $139.6M | $29.6M | — | — |
| Property, plant and equipment | $44.8M | $48.3M | $57.4M | $61.9M | $19.6M | $11.8M | $14.1M | $11.5M | — | — |
| Total assets | $334.2M | $270.3M | $225.1M | $292.7M | $396.5M | $244.8M | $157.3M | $41.7M | — | — |
| Accounts payable | $13.0M | $6.4M | $14.9M | $12.9M | $9.2M | $8.3M | $7.3M | $6.6M | — | — |
| Short-term debt | — | — | — | — | — | — | — | $5.0M | — | — |
| Total current liabilities | $39.6M | $31.1M | $47.2M | $33.1M | $31.3M | $40.6M | $50.0M | $57.9M | — | — |
| Total liabilities | $73.0M | $67.3M | $95.7M | $74.6M | $86.2M | $49.9M | $50.6M | $58.7M | — | — |
| Retained earnings | -$631.3M | -$550.0M | -$468.7M | -$360.4M | -$247.1M | -$181.9M | -$140.6M | -$115.5M | — | — |
| Total equity | $261.2M | $203.0M | $129.4M | $218.1M | $310.3M | $194.9M | $106.7M | -$106.4M | -$92.6M | -$69.8M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$74.9M | -$45.1M | -$56.3M | -$70.2M | -$70.8M | -$42.7M | -$18.1M | $5.6M | $290.0K | — |
| Depreciation and amortisation | $10.0M | $10.9M | $11.3M | $8.4M | $6.0M | $5.8M | $4.7M | $3.1M | $1.2M | — |
| Stock-based compensation | $9.4M | $10.7M | $14.1M | $19.4M | $14.4M | $8.2M | $4.9M | $1.3M | $753.0K | — |
| Capital expenditure | $4.5M | $1.6M | $10.9M | $49.9M | $11.1M | $3.2M | $8.4M | $7.9M | $5.2M | — |
| Investing cash flow | -$22.6M | -$35.1M | $13.1M | $52.5M | -$60.1M | -$65.1M | -$81.6M | -$7.9M | -$5.2M | — |
| Financing cash flow | $130.3M | $114.7M | $11.0M | $1.4M | $169.7M | $121.3M | $134.9M | -$591.0K | $16.4M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001193125-26-076615.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | $9.4M | $37.8M | $65.2M | $78.6M | $85.5M | $65.0M | $73.5M | $84.6M | $69.6M |
| Gross profit | — | -$2.3M | $11.8M | $22.1M | $20.1M | $31.7M | $13.3M | $18.2M | $26.8M | $15.8M |
| Net income | — | -$23.6M | -$19.9M | -$25.1M | -$41.3M | -$65.2M | -$113.3M | -$108.3M | -$81.3M | -$81.3M |
Recent filings and events
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Results announced Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Other event Item 8.01
- Results announced Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 8071
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| NTRA | Natera, Inc. | $58.23B | — | 35.9% |
| DGX | QUEST DIAGNOSTICS INC | $26.70B | 27.6x | 11.8% |
| LH | LABCORP HOLDINGS INC. | $26.68B | 31.4x | 7.2% |
| GH | Guardant Health, Inc. | $22.69B | — | 32.9% |
| CAI | Caris Life Sciences, Inc. | $9.04B | — | 97.0% |
| GRAL | GRAIL, Inc. | $5.92B | — | 17.2% |
| RDNT | RadNet, Inc. | $5.54B | — | 11.5% |
| BLLN | BillionToOne, Inc. | $5.00B | 769.8x | 100.0% |